Mirre M. Trines

Willem J.M. Mulder Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Eindhoven, 5600 MB The Netherlands Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, 6525 GA The Netherlands Search for more papers by this author

Nucleic Acid Insights 2025; 2(8), 171–184 DOI: 10.18609/nuc.2025.026 Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of B cell malignancies over the past decades. Despite its success, CAR-T cell therapy remains limited by high costs, complex ex vivo manufacturing, and the risk of severe adverse effects.

Abstract Nucleic acid therapeutics are used for silencing, expressing or editing genes in vivo. However, their systemic stability and targeted delivery to bone marrow resident cells remains a challenge. In this study we present a nanotechnology platform based on natural lipoproteins, designed for delivering small interfering RNA (siRNA), antisense oligonucleotides and messenger RNA to myeloid cells and haematopoietic stem and progenitor cells in the bone marrow.